68Gallium-Arginine-Glycine-Aspartic Acid and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Chondroblastic Osteosarcoma of the Skull

Akintunde Orunmuyi; Moshe Modiselle; Thabo Lengana; Thomas Ebenhan; Mariza Vorster; Mike Sathekge

doi:10.1007/s13139-016-0400-6

⁶⁸Gallium-Arginine-Glycine-Aspartic Acid and ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Chondroblastic Osteosarcoma of the Skull

Nucl Med Mol Imaging. 2017 Sep;51(3):271-273. doi: 10.1007/s13139-016-0400-6. Epub 2016 Feb 12.

Authors

Akintunde Orunmuyi¹, Moshe Modiselle¹, Thabo Lengana¹, Thomas Ebenhan¹, Mariza Vorster¹, Mike Sathekge¹

Affiliation

¹ Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Private Bag X169, Pretoria, 0001 South Africa.

Abstract

We report the case of a 32 year-old male with Chondroblastic Osteosarcoma of the skull, which was imaged with both ¹⁸[F]fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) and ⁶⁸Gallium-arginine-glycine-aspartic acid (⁶⁸Ga-RGD) PET/CT. The ¹⁸F-FDG PET/CT did not demonstrate the tumour, whereas the ⁶⁸Ga-RGD PET/CT clearly depicted a left-sided frontal tumour. ⁶⁸Ga-RGD PET/CT may be a clinically useful imaging modality for early detection of recurrent osteosarcoma, considering the limitations of ¹⁸F-FDG PET in a setting of low glycolytic activity.

Keywords: 18F-FDG; 68Ga-RGD; Chondroblastic Osteosarcoma; PET/CT.